FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)

FDA decision on Lorundrostat on or before December 22, 2026 If the FDA's decision on Lorundrostat by Mineralys Therapeutics on or before December 22, 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. This market will close early if the FDA issues a decision on Lorundrostat before Dec 23, 2026